Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Hologic reports Q1 revenue surpassing guidance

EditorBrando Bricchi
Published 01/07/2024, 04:28 PM
Updated 01/07/2024, 04:28 PM

MARLBOROUGH, Mass. - Hologic, Inc. (NASDAQ:HOLX), a medical technology company, announced preliminary revenue for its first fiscal quarter ended December 30, 2023, surpassing its previous revenue guidance. The company expects to report approximately $1,013.1 million in total revenues, a decrease of 5.7% from the prior year or 6.4% in constant currency. However, these figures exceed the company's most recent guidance of $960 to $985 million.

Steve MacMillan, Hologic's Chairman, President, and CEO, highlighted the company's strong organic revenue performance, excluding COVID-19 impacts, estimating over 9% growth compared to the prior year when adjusted for four fewer selling days.

By division, the Diagnostics segment saw a decline, with reported revenues of $447.8 million compared to $559.3 million in the previous year. However, organic Molecular Diagnostics, excluding COVID-19, grew by 2.8%. The Breast Health division experienced a 13% increase, reporting $377.7 million in revenues. The GYN Surgical segment also saw growth with a 5.3% increase to $162.2 million. Skeletal Health revenues declined by 4.5% to $25.4 million.

Hologic's organic revenue, excluding COVID-19, reached $952.7 million, representing a 6.1% increase in reported currency and a 5.2% rise in constant currency. This performance exceeds the company's previous guidance of 1.0% to 3.7% growth.

The company has not completed its financial close processes for the quarter, and GAAP financial results have not been finalized. However, non-GAAP diluted earnings per share (EPS) are expected to be towards the high end of the $0.92 to $0.97 guidance range.

Hologic plans to release its full financial results for the first quarter on February 1, 2024. The company will also provide updated financial guidance for the second quarter and the full fiscal year of 2024 after its quarterly forecasting process is complete.

These preliminary results were shared in advance of Hologic's participation in the 42nd Annual J.P. Morgan Healthcare Conference, which begins Monday. The company will post its conference presentation on its investor website and will also provide a live webcast of its presentation and Q&A session.

It is important to note that the information provided is based on a press release statement and may be subject to revisions. The non-GAAP financial measures presented are intended to supplement GAAP measures and may differ from similar measures used by other companies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.